Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2022

Open Access 01-12-2022 | Artificial Intelligence | Study protocol

Effect of an artificial intelligence-assisted tool on non-valvular atrial fibrillation anticoagulation management in primary care: protocol for a cluster randomized controlled trial

Authors: Xueying Ru, Lan Zhu, Yunhui Ma, Tianhao Wang, Zhigang Pan

Published in: Trials | Issue 1/2022

Login to get access

Abstract

Background

Atrial fibrillation (AF) is one of the most common cardiac arrhythmia diseases. Thromboembolic prophylaxis plays an essential role in AF therapy, but at present, general practitioners (GPs) are presumed to lack the knowledge and enthusiasm for AF management. Clinical decision support systems (CDSS), assisted by artificial intelligence, help primary care providers (PCPs) make quick, individualized, and correct clinical decisions. This primary aim of the study is to identify whether the promotion of the CDSS would improve the primary care provided to patients with AF. The secondary objectives are mainly to assess the health-economic and clinical benefits from using the CDSS, and the improvement of GPs’ AF management capability.

Methods

This study will be a prospective cluster randomized controlled trial, conducted among 14 community health centers in Shanghai which were randomized as the intervention group and control group in a ratio of 1:1. The intervention group will use the CDSS in the consultation of patients with AF and the control group will maintain their usual care. The trial will include 498 patients with AF and the follow-up period will be 12 months. The primary outcome is set as the proportion of antithrombotic treatment prescriptions in agreement with recommendations in the latest China’s AF-related guidelines. The secondary outcomes are the frequency of consultation, the compliance rate of international normalized ratio (INR) in patients with warfarin, stroke morbidity, treatment compliance, medication satisfaction, and the cost-benefit analysis. Per-protocol (PP) analysis and the intention-to-treat (ITT) analysis will be conducted.

Discussion

This study aims to identify whether the application of CDSS to manage patients with AF in China’s community health centers would bring benefits for patients, physicians, and health economics.

Trial registration

Registry name: 非瓣膜性房颤社区AI辅助管理工具研发及推广效果研究 (Development and promotion of an AI-assisted tool for NVAF management in primary care); registry number: ChiCTR2100052307; registration date: Nov. 22nd, 2021; http://​www.​chictr.​org.​cn/​showproj.​aspx?​proj=​133849.
Appendix
Available only for authorised users
Literature
1.
Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56–e528.CrossRefPubMed
2.
Zhou Z, Hu D, Chen J, Zhang R, Li K, Zhao X. An epidemiological survey of atrial fibrillation in China. Chin J Int Med. 2004;43(7):491–4.
3.
Chiang CE, Okumura K, Zhang S, Chao TF, Siu CW, Wei Lim T, et al. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm. 2017;33(4):345–67.CrossRefPubMedPubMedCentral
4.
Shu Z, Minyan Y, Congxin H, Dejia H, Kejiang C, Jun Z, et al. Guideline of stroke prevention in Chinese patients with atrial fibrillation (2017). Chin J Cardiac Arrhyth. 2018;22(1):17–30.
5.
Wang Z, Chen Z, Wang X, Zhang L, Li S, Tian Y, et al. The Disease Burden of Atrial Fibrillation in China from a National Cross-sectional Survey. Am J Cardiol. 2018;122(5):793–8.CrossRefPubMed
6.
Wang KL, Lip GY, Lin SJ, Chiang CE. Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-Analysis. Stroke. 2015;46(9):2555–61.CrossRefPubMedPubMedCentral
7.
Committee of Cardiocerebral and Vascular Disease of Chinese Gerontological Society Chinese Expert Consensus Group on Application of New Oral Anticoagulation Drugs in Patients with Nonvalvular Atrial Fibrillation. The current situation and future of the atrial fibrillation anticoagulation in China. Chin J Cardiovasc Res. 2014;12(9):769–70.
8.
Kirchhof P. The future of atrial fibrillation management: integrated care and stratified therapy. Lancet. 2017;390(10105):1873–87.CrossRefPubMed
9.
Population WCfECotMoafiE, Society CG, Geriatrics EBoCJo. Expert consensus on the management of atrial fibrillation in elderly population(2016). Chinese. J Geriatr. 2016;35(9):915–28.
10.
11.
Gu J, Song H, Zhou Y, Cheng W, Dai L, Li Z. Management window for patients with atrial fibrillation in community health center. Chin J Gen Practitioners. 2013;12(6):463–5.
12.
He K, Wu Z. Advances in artificial intelligence in prediction of atrial fibrillation. Chin J Clin Thorac Cardiovasc Surg. 2020;27(12):1472–8.
13.
Kawamoto K, Houlihan CA, Balas EA, Lobach DF. Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success. Bmj. 2005;330(7494):765.CrossRefPubMedPubMedCentral
14.
Wess ML, Saleem JJ, Tsevat J, Luckhaupt SE, Johnston JA, Wise RE, et al. Usability of an atrial fibrillation anticoagulation decision-support tool. J Prim Care Community Health. 2011;2(2):100–6.CrossRefPubMed
15.
Bright TJ, Wong A, Dhurjati R, Bristow E, Bastian L, Coeytaux RR, et al. Effect of clinical decision-support systems: a systematic review. Ann Intern Med. 2012;157(1):29–43.CrossRefPubMed
16.
Kessler ME, Carter RE, Cook DA, Kor DJ, McKie PM, Pencille LJ, et al. Impact of electronic clinical decision support on adherence to guideline-recommended treatment for hyperlipidaemia, atrial fibrillation and heart failure: protocol for a cluster randomised trial. BMJ Open. 2017;7(12):e019087.CrossRefPubMedPubMedCentral
17.
Klarenbeek SE, Weekenstroo HHA, Sedelaar JPM, Fütterer JJ, Prokop M, Tummers M. The Effect of Higher Level Computerized Clinical Decision Support Systems on Oncology Care: A Systematic Review. Cancers (Basel). 2020;12(4):1032.CrossRef
18.
Arts DL, Abu-Hanna A, Medlock SK, van Weert HC. Effectiveness and usage of a decision support system to improve stroke prevention in general practice: A cluster randomized controlled trial. PLoS One. 2017;12(2):e0170974.CrossRefPubMedPubMedCentral
19.
Cox JL, Parkash R, Foster GA, Xie F, MacKillop JH, Ciaccia A, et al. Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF): A cluster randomized trial of a computerized clinical decision support tool. Am Heart J. 2020;224:35–46.CrossRefPubMed
20.
Eckman MH, Lip GY, Wise RE, Speer B, Sullivan M, Walker N, et al. Impact of an Atrial Fibrillation Decision Support Tool on thromboprophylaxis for atrial fibrillation. Am Heart J. 2016;176:17–27.CrossRefPubMed
21.
Karlsson LO, Nilsson S, Bång M, Nilsson L, Charitakis E, Janzon M. A clinical decision support tool for improving adherence to guidelines on anticoagulant therapy in patients with atrial fibrillation at risk of stroke: A cluster-randomized trial in a Swedish primary care setting (the CDS-AF study). PLoS Med. 2018;15(3):e1002528.CrossRefPubMedPubMedCentral
22.
Piazza G, Hurwitz S, Galvin CE, Harrigan L, Baklla S, Hohlfelder B, et al. Alert-based computerized decision support for high-risk hospitalized patients with atrial fibrillation not prescribed anticoagulation: a randomized, controlled trial (AF-ALERT). Eur Heart J. 2020;41(10):1086–96.PubMed
23.
van Doorn S, Rutten FH, O'Flynn CM, Oudega R, Hoes AW, Moons KGM, et al. Effectiveness of CHA(2)DS(2)-VASc based decision support on stroke prevention in atrial fibrillation: A cluster randomised trial in general practice. Int J Cardiol. 2018;273:123–9.CrossRefPubMed
24.
Steinberg BA, Gao H, Shrader P, Pieper K, Thomas L, Camm AJ, et al. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. Am Heart J. 2017;194:132–40.CrossRefPubMed
25.
Guo Y, Lane DA, Wang L, Zhang H, Wang H, Zhang W, et al. Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation. J Am Coll Cardiol. 2020;75(13):1523–34.CrossRefPubMed
26.
Cruz Rivera S, Liu X, Chan AW, Denniston AK, Calvert MJ, Spirit AI, et al. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension. Nat Med. 2020;26(9):1351–63.CrossRefPubMedPubMedCentral
27.
Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355:i5239.CrossRefPubMedPubMedCentral
28.
Chinese Medical Association, Chinese Medical Journals Publishing House, Chinese Society of General Practice, Editorial Board of Chinese Journal of General Practitioners of Chinese Medical Association, Disease EGoGfPCoC. Guideline for primary care of atrial fibrillation (2019). Chin J Gen Pract. 2020;19(6):465–73.
29.
Chinese Cardiovascular Disease Society Editorial Board Committee of Cardiocerebral and Vascular Disease of Chinese Gerontological Society. Chinese Expert Consensus on the Clinical Application of Warfarin (Basic Version). Chin J Gen Practitioners. 2013;36(5):471–7.
30.
Gallagher AM, Setakis E, Plumb JM, Clemens A, Staa TV. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost. 2011;106(5):968–77.CrossRefPubMed
31.
Wu S. A Study of Patients’ Satisfaction between 3-A-Grade General Hospital and Community Health Service Centre in Guangzhou. Guangzhou: Guangzhou Medical University; 2016.
32.
Ye S, Pan Z, Liu W, Zhu L. General Practitioners’ KAP Questionnaire on Anticoagulation in Patients with Nonvalvular Atrial Fibrillation Using Delphi Method. Chin Gen Pract. 2018;21(33):4118–26.
33.
Ye S, Wang T, Liu A, Yu Y, Pan Z, Gu J. A study of knowledge, attitudes, and practices of primary care physicians toward anticoagulant therapy in patients with non-valvular atrial fibrillation in Shanghai, China. BMC Fam Pract. 2020;21(1):165.CrossRefPubMedPubMedCentral
34.
Guo Y. Analysis of current status of anticoagulant therapy in patients with atrial fibrillation in community. Diet health. 2020;40:292.
35.
Guo Y, Lane DA, Wang L, Chen Y, Lip GYH. Mobile Health (mHealth) technology for improved screening, patient involvement and optimising integrated care in atrial fibrillation: The mAFA (mAF-App) II randomised trial. Int J Clin Pract. 2019;73(7):e13352.CrossRefPubMed
36.
Wolowacz SE, Samuel M, Brennan VK, Jasso-Mosqueda JG, Van Gelder IC. The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace. 2011;13(10):1375–85.CrossRefPubMed
37.
Zhang L, Yin C, Hu S. The Illness Burden Brought by Atrial Fibrillation in China. Chin Health Econ. 2013;32(12):5–7.
38.
Qi Y, Jin X, Li S, Cao J, Chen Y, Tang B, et al. Epidemiological characteristics and anticoagulant therapy status of atrial fibrillation in elderly community residents in Shanghai. Chin J Clin Med. 2018;25(1):1–4.
39.
Xue H, Zeng G, Yingmin L. Survey on the treatment of anticoagulation in 212 patients with atrial fibrillation in the community of Shanghai. South China J Cardiovasc Dis. 2020;26(3):321–3.
40.
Kornej J, Börschel CS, Benjamin EJ, Schnabel RB. Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights. Circ Res. 2020;127(1):4–20.CrossRefPubMedPubMedCentral
41.
Wang QC, Wang ZY. Big Data and Atrial Fibrillation: Current Understanding and New Opportunities. J Cardiovasc Transl Res. 2020;13(6):944–52.CrossRefPubMed
42.
Holt TA, Dalton AR, Kirkpatrick S, Hislop J, Marshall T, Fay M, et al. Barriers to a software reminder system for risk assessment of stroke in atrial fibrillation: a process evaluation of a cluster randomised trial in general practice. Br J Gen Pract. 2018;68(677):e844–e51.CrossRefPubMedPubMedCentral
43.
Wang Y, Bajorek B. Selecting antithrombotic therapy for stroke prevention in atrial fibrillation: Health professionals’ feedback on a decision support tool. Health Informatics J. 2018;24(3):309–22.CrossRefPubMed
Metadata
Title
Effect of an artificial intelligence-assisted tool on non-valvular atrial fibrillation anticoagulation management in primary care: protocol for a cluster randomized controlled trial
Authors
Xueying Ru
Lan Zhu
Yunhui Ma
Tianhao Wang
Zhigang Pan
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Trials / Issue 1/2022
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-022-06250-8

Other articles of this Issue 1/2022

Trials 1/2022 Go to the issue

Research

Development of a measure to assess the quality of proxy decisions about research participation on behalf of adults lacking capacity to consent: the Combined Scale for Proxy Informed Consent Decisions (CONCORD scale)

Study protocol

Effects of Bushen-Jiangya granules on blood pressure and pharmacogenomic evaluation in low-to-medium-risk hypertensive patients: study protocol for a randomized double-blind controlled trial

Correction

Correction: Trial Forge Guidance 3: randomised trials and how to recruit and retain individuals from ethnic minority groups—practical guidance to support better practice

Study protocol

Assessing the effect of an educational intervention on early childhood development among Mexican preschool children in the state of Oaxaca: a study protocol of a cluster randomized stepped-wedge trial

Study protocol

Telehealth exercise to Improve Physical function and frailty in patients with multiple myeloma treated with autologous hematopoietic Stem cell transplantation (TIPS): protocol of a randomized controlled trial

Study protocol

Simplifying and optimising management of acute malnutrition in children aged 6 to 59 months: study protocol for a 3 arms community-based individually randomised controlled trial in decentralised Niger